<DOC>
	<DOCNO>NCT00874497</DOCNO>
	<brief_summary>Phase 2a multicenter , randomize , double-blind , placebo-controlled study ass pharmacodynamics , efficacy , safety tetomilast patient emphysema .</brief_summary>
	<brief_title>Pilot Study Tetomilast Chronic Obstructive Pulmonary Disease ( COPD ) Associated With Emphysema</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Emphysema</mesh_term>
	<criteria>Male female , 4075 yr old , inclusive . Rating great equal 1 Goddard scale assessment emphysema severity HRCT . FEV1 : FVC great 70 % predict . At least 1 documented COPD exacerbation within past year within 8 week randomization . Current former smoker cigarette smoke history least 20 packyears ( equivalent ) whose smoke status change 60 day prior screen . Patients asthma , active tuberculosis bronchiectasis . A respiratory tract infection within 30 day prior screen visit . Any malignancy within last 5 year exception nonmelanomatous skin cancer . Uncontrolled cardiovascular , endocrine , blood , nervous system disorder . Uncontrolled condition COPD exacerbation level 2 3 8week period prior randomization . Systemic use corticosteroid immunosuppressive agent within 30 day screen visit . Subjects take anticoagulant .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>